药品注册申请号:200882
申请类型:ANDA (仿制药申请)
申请人:SUN PHARM
申请人全名:SUN PHARMACEUTICAL INDUSTRIES LTD
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 20MG BASE/VIAL No No None 2013/03/18 2013/03/18 Discontinued
002 ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL No No AP 2013/03/18 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2015/04/14 SUPPL-3(补充) Approval Labeling STANDARD
2015/04/14 SUPPL-2(补充) Approval Labeling STANDARD
2013/03/18 ORIG-1(原始申请) Approval Not Applicable
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:ESOMEPRAZOLE SODIUM 剂型/给药途径:INJECTABLE;INTRAVENOUS 规格:EQ 40MG BASE/VIAL 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021689 002 NDA NEXIUM IV ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Discontinued Yes No AP 2005/03/31 ASTRAZENECA
200882 002 ANDA ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Discontinued No No AP 2013/03/18 SUN PHARM
205379 001 ANDA ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Discontinued No No AP 2015/09/25 ACCORD HLTHCARE
204657 002 ANDA ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Prescription No No AP 2016/08/10 EUGIA PHARMA
207181 001 ANDA ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Prescription No No AP 2017/03/06 DEVA HOLDING AS
203349 002 ANDA ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Prescription No No AP 2020/04/01 GLAND PHARMA LTD
215732 001 ANDA ESOMEPRAZOLE SODIUM ESOMEPRAZOLE SODIUM INJECTABLE;INTRAVENOUS EQ 40MG BASE/VIAL Prescription No Yes AP 2022/02/10 SLATE RUN PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database